“…AKT, v-akt murine thymoma viral oncogene homolog; BDGF, brain-derived growth factor; DAG, diacylglycerol; ERK, extracellular signal-regulated kinase; GAB1, GRB2-associated-binding protein 1; GRB2, growth factor receptor-bound protein 2; IP3, inositol trisphosphate; MEK, mitogenactivated protein kinase; NGF, nerve growth factor; NTF-3, neurotrophin 3; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein kinase C; PLC, phospholipase C; RAF, rapidly accelerated fibrosarcoma kinase; RAS, rat sarcoma kinase; SHC, Src homology 2 domain containing. Reproduced with permission from Amatu A, Sartore-Bianchi A, Siena S. ESMO Open 2016;1(2):e000023 NCT02637687, NCT02576431) have shown durable overall response rates of 93% in a pediatric phase I/II trial and 75% in a combined adult and pediatric phase I/II trial [23,59]. Adverse events were predominantly grade 1 or grade 2 with no grade 3 or grade 4 adverse events attributable to larotrectinib seen in more than 5% of the patients regardless of tumor type or fusion partner [23,59].…”